The bioinformatics and sequencing firm, formerly known as WuXi NextCode, will develop a population clinicogenomic database to support Emory's research.
The grant will allow Weill Cornell to study genetic, social, and clinical factors that might explain why COVID-19 disproportionally affects minorities in the US.
Genuity, formerly known as WuXi NextCode, will sequence, analyze, and harmonize samples from Vanderbilt's biobank to inform biomarker and drug discovery.
By screening more than 1,500 drugs against patient-derived glioblastoma cells, researchers tracked down tumor alterations with apparent ties to proteasome inhibitor response.
The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
British bioinformatics firm PrecisionLife has mined the UK Biobank to identify genetic risk factors for late-stage COVID-19 patients developing sepsis.
Backed by BARDA, Merck and Institute for Systems Biology are studying multiomic data to understand infection pathways and find biomarkers for symptom risk.
